Search Results - "Jindrich, Spinar"

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure by Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R, Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez

“…Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of…”
Get full text

Clinical picture and risk prediction of short-term mortality in cardiogenic shock by Harjola, Veli-Pekka, Lassus, Johan, Sionis, Alessandro, Køber, Lars, Tarvasmäki, Tuukka, Spinar, Jindrich, Parissis, John, Banaszewski, Marek, Silva-Cardoso, Jose, Carubelli, Valentina, Di Somma, Salvatore, Tolppanen, Heli, Zeymer, Uwe, Thiele, Holger, Nieminen, Markku S, Mebazaa, Alexandre

“…Aims The aim of this study was to investigate the clinical picture and outcome of cardiogenic shock and to develop a risk prediction score for short‐term…”
Get full text

Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World by Shah, Ravi, MD, Gayat, Etienne, MD, MS, Januzzi, James L., MD, Sato, Naoki, MD, PhD, Cohen-Solal, Alain, MD, PhD, diSomma, Salvatore, MD, Fairman, Enrique, MD, Harjola, Veli-Pekka, MD, Ishihara, Shiro, MD, Lassus, Johan, MD, PhD, Maggioni, Aldo, MD, Metra, Marco, MD, PhD, Mueller, Christian, MD, Mueller, Thomas, MD, Parenica, Jiri, MD, MS, Pascual-Figal, Domingo, MD, PhD, Peacock, William Frank, MD, Spinar, Jindrich, MD, PhD, van Kimmenade, Roland, MD, PhD, Mebazaa, Alexandre, MD

“…Objectives This study sought to define the relationship between body mass index (BMI) and mortality in heart failure (HF) across the world and to identify…”
Get full text

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial by Teerlink, John R, Prof, Felker, G Michael, Prof, McMurray, John J V, Prof, Solomon, Scott D, Prof, Adams, Kirkwood F, MD, Cleland, John G F, Prof, Ezekowitz, Justin A, MBBCh, Goudev, Assen, Prof, Macdonald, Peter, Prof, Metra, Marco, Prof, Mitrovic, Veselin, Prof, Ponikowski, Piotr, Prof, Serpytis, Pranas, Prof, Spinar, Jindrich, Prof, Tomcsányi, János, Prof, Vandekerckhove, Hans J, MD, Voors, Adriaan A, Prof, Monsalvo, Maria Laura, MD, Johnston, James, PhD, Malik, Fady I, MD, Honarpour, Narimon, MD

“…Summary Background Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac…”
Get full text

Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients by Léopold, Valentine, Gayat, Etienne, Pirracchio, Romain, Spinar, Jindrich, Parenica, Jiri, Tarvasmäki, Tuukka, Lassus, Johan, Harjola, Veli-Pekka, Champion, Sébastien, Zannad, Faiez, Valente, Serafina, Urban, Philip, Chua, Horng-Ruey, Bellomo, Rinaldo, Popovic, Batric, Ouweneel, Dagmar M., Henriques, José P. S., Simonis, Gregor, Lévy, Bruno, Kimmoun, Antoine, Gaudard, Philippe, Basir, Mir Babar, Markota, Andrej, Adler, Christoph, Reuter, Hannes, Mebazaa, Alexandre, Chouihed, Tahar

“…Objective Catecholamines have been the mainstay of pharmacological treatment of cardiogenic shock (CS). Recently, use of epinephrine has been associated with…”
Get full text

Precipitating factors and 90‐day outcome of acute heart failure: a report from the intercontinental GREAT registry by Arrigo, Mattia, Gayat, Etienne, Parenica, Jiri, Ishihara, Shiro, Zhang, Jian, Choi, Dong‐Ju, Park, Jin Joo, Alhabib, Khalid F., Sato, Naoki, Miro, Oscar, Maggioni, Aldo P., Zhang, Yuhui, Spinar, Jindrich, Cohen‐Solal, Alain, Iwashyna, Theodore J., Mebazaa, Alexandre

“…Aims Several clinical conditions may precipitate acute heart failure (AHF) and influence clinical outcome. In this study we hypothesized that precipitating…”
Get full text

Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study by Lassus, Johan, Gayat, Etienne, Mueller, Christian, Peacock, W.Frank, Spinar, Jindrich, Harjola, Veli-Pekka, van Kimmenade, Roland, Pathak, Atul, Mueller, Thomas, diSomma, Salvatore, Metra, Marco, Pascual-Figal, Domingo, Laribi, Said, Logeart, Damien, Nouira, Semir, Sato, Naoki, Potocki, Michael, Parenica, Jiri, Collet, Corinne, Cohen-Solal, Alain, Januzzi, James L, Mebazaa, Alexandre

“…Abstract Aim This study aims to evaluate the incremental value of plasma biomarkers to traditional clinical variables for risk stratification of 30-day and…”
Get full text

Diagnostic and Prognostic Utility of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Patients with Cardiovascular Diseases - Review by Helanova, Katerina, Spinar, Jindrich, Parenica, Jiri

“…NGAL (neutrophil gelatinase-associated lipocalin) is an acute phase protein, participating in antibacterial immunity. NGAL forms a complex with…”
Get full text

Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction - A report from FAR NHL prospective registry by Spinar, Jindrich, Spinarova, Lenka, Malek, Filip, Ludka, Ondrej, Krejci, Jan, Ostadal, Petr, Vondrakova, Dagmar, Labr, Karel, Spinarova, Monika, Pavkova Goldbergova, Monika, Benesova, Klara, Jarkovsky, Jiri, Parenica, Jiri

“…According to guidelines, the prognosis of patients with chronic heart failure can be predicted by determining the levels of natriuretic peptides, the NYHA…”
Get full text

GRACE Score among Six Risk Scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) Demonstrated the Best Predictive Value for Prediction of Long-Term Mortality in Patients with ST-Elevation Myocardial Infarction by Littnerova, Simona, Kala, Petr, Jarkovsky, Jiri, Kubkova, Lenka, Prymusova, Krystyna, Kubena, Petr, Tesak, Martin, Toman, Ondrej, Poloczek, Martin, Spinar, Jindrich, Dusek, Ladislav, Parenica, Jiri

“…To compare the prognostic accuracy of six scoring models for up to three-year mortality and rates of hospitalisation due to acute decompensated heart failure…”
Get full text

Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry by Spinar, Jindrich, Parenica, Jiri, Vitovec, Jiri, Widimsky, Petr, Linhart, Ales, Fedorco, Marian, Malek, Filip, Cihalik, Cestmír, Spinarová, Lenka, Miklik, Roman, Felsoci, Marian, Bambuch, Miroslav, Dusek, Ladislav, Jarkovsky, Jiri

“…The prognosis of patients hospitalized with acute heart failure (AHF) is poor and risk stratification may help clinicians guide care. The objectives of the…”
Get full text

Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock by Jäntti, Toni, Tarvasmäki, Tuukka, Harjola, Veli-Pekka, Parissis, John, Pulkki, Kari, Javanainen, Tuija, Tolppanen, Heli, Jurkko, Raija, Hongisto, Mari, Kataja, Anu, Sionis, Alessandro, Silva-Cardoso, Jose, Banaszewski, Marek, Spinar, Jindrich, Mebazaa, Alexandre, Lassus, Johan

“…The prevalence of hypoalbuminemia, early changes of plasma albumin (P-Alb) levels, and their effects on mortality in cardiogenic shock are unknown. P-Alb was…”
Get full text

AHEAD score — Long-term risk classification in acute heart failure by Spinar, Jindrich, Jarkovsky, Jiri, Spinarova, Lenka, Mebazaa, Alexandre, Gayat, Etienne, Vitovec, Jiri, Linhart, Ales, Widimsky, Petr, Miklik, Roman, Zeman, Kamil, Belohlavek, Jan, Malek, Filip, Felsoci, Marian, Kettner, Jiri, Ostadal, Petr, Cihalik, Cestmir, Vaclavik, Jan, Taborsky, Miloš, Dusek, Ladislav, Littnerova, Simona, Parenica, Jiri

“…Abstract Background The role of co-morbidities in the prognosis of patients hospitalized for AHF was examined using the AHEAD ( A — atrial fibrillation, H —…”
Get full text

Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction by Lokaj, Petr, Spinar, Jindrich, Spinarova, Lenka, Malek, Filip, Ludka, Ondrej, Krejci, Jan, Ostadal, Petr, Vondrakova, Dagmar, Labr, Karel, Spinarova, Monika, Pavkova Goldbergova, Monika, Miklikova, Marie, Helanova, Katerina, Parenicova, Ilona, Jakubo, Vladimir, Benesova, Klara, Miklik, Roman, Jarkovsky, Jiri, Ondrus, Tomas, Parenica, Jiri

“…Background The identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic…”
Get full text

Diabetes mellitus in stable chronic heart failure and the combination with humoral activation, their association, and prediction of 2‐year adverse outcomes. Data from the FAR NHL registry by Labr, Karel, Spinar, Jindrich, Parenica, Jiri, Spinarova, Lenka, Krejci, Jan, Malek, Filip, Ostadal, Petr, Ludka, Ondrej, Jarkovsky, Jiri, Benesova, Klara, Labrova, Ruzena, Spinarova, Monika

“…Background/Aim The study aims to describe the role of diabetes in patients with heart failure. Methods In all, 1052 chronic heart failure patients were…”
Get full text

Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I by Bonaca, Marc, MD, Scirica, Benjamin, MD, MPH, Sabatine, Marc, MD, MPH, Dalby, Anthony, MD, Spinar, Jindrich, MD, Murphy, Sabina A., MPH, Jarolim, Peter, MD, PhD, Braunwald, Eugene, MD, Morrow, David A., MD, MPH

“…Objectives The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a…”
Get full text

The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis by Pirracchio, Romain, Parenica, Jiri, Resche Rigon, Matthieu, Chevret, Sylvie, Spinar, Jindrich, Jarkovsky, Jiri, Zannad, Faiez, Alla, François, Mebazaa, Alexandre

“…The best catecholamine regimen for cardiogenic shock has been poorly evaluated. When a vasopressor is required to treat patients with the most severe form of…”
Get full text

Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort by Teixeira, Antonio, Parenica, Jiri, Park, Jin Joo, Ishihara, Shiro, AlHabib, Khalid F., Laribi, Said, Maggioni, Aldo, Miró, Òscar, Sato, Naoki, Kajimoto, Katsuya, Cohen-Solal, Alain, Fairman, Enrique, Lassus, Johan, Mueller, Christian, Peacock, William F., Januzzi Jr, James L., Choi, Dong-Ju, Plaisance, Patrick, Spinar, Jindrich, Mebazaa, Alexandre, Gayat, Etienne

“…Aims To assess, according to age groups, patients' characteristics according to region of origin, the chronic therapeutic management, prognostic utility of…”
Get full text

Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients – Multiple biomarkers prospective cohort study by Parenica, Jiri, Kala, Petr, Pavkova, Monika Goldbergova, Tomandl, Josef, Spinar, Jindrich, Littnerova, Simona, Jarkovsky, Jiri, Mebazaa, Alexandre, Tomandlová, Marie, Dastych, Milan, Gottwaldová, Jana, Gayat, Etienne

“…Abstract Background Blood-based biomarkers have a prognostic value in patients with myocardial infarction. The aim of our prospective observational cohort…”
Get full text

Efficacy and safety of vorapaxar as approved for clinical use in the United States by Magnani, Giulia, Bonaca, Marc P, Braunwald, Eugene, Dalby, Anthony J, Fox, Keith A A, Murphy, Sabina A, Nicolau, José Carlos, Oude Ophuis, Ton, Scirica, Benjamin M, Spinar, Jindrich, Theroux, Pierre, Morrow, David A

“…Vorapaxar is a protease-activated receptor-1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular…”
Get full text